Although benefits were observed in older patients, they were less pronounced and did not reach statistical significance for OS (HR 0.86; 95% CI 0.62–1.19) or PFS (HR 0.84; 95% CI 0.65–1.09).
← all excerpts
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
1
—
—